BCLI BRAINSTORM CELL THERAPEUTICS INC.

CIK 0001137883 50 ready 8-Ks latest May 28, 2026, 4:05 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing May 28, 2026, 4:05 PM ET

Top materiality 0.85

Event mix other_material ×16 · regulatory ×14 · earnings ×9

Sentiment 10 pos · 16 neg · 24 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for BCLI

Highest-materiality recent filing

BrainStorm delisted from Nasdaq; shares to trade on OTCQB from July 18

July 17, 2025, 7:59 PM ET other material materiality 0.85 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Delisting due to non-compliance with Nasdaq minimum shareholder equity rule (Rule 5550(b)(1)).
Nasdaq trading suspended at open on July 18, 2025; company received notice on July 16.

Read filing →

May 28, 2026, 4:05 PM ET leadership materiality 0.65 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

BrainStorm appoints former FDA official Peter Pitts to Board ahead of ALS trial

Appointed Peter Pitts, former FDA Associate Commissioner, to the Board effective May 25, 2026.
May 15, 2026, 5:00 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases

BrainStorm Q1 net loss $2.1M; cash below $0.2M; NurOwn Phase 3 preparations ongoing

Net loss $2.1M ($0.19 per share) vs $2.9M ($0.45) in Q1 2025; operating loss $2.0M.
March 31, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

BrainStorm reports FY2025 net loss $10.3M; secures $2M post-year-end for Phase 3b

Cash, equivalents, restricted cash $0.3M at Dec 31, 2025; raised $2M in Feb 2026 private placements.
February 27, 2026, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 3.02 item 5.02 item 9.01 ◈ Equity Issuances ×2◈ Material Agreements

Brainstorm Cell Therapeutics raises $1M in private placement, increases share pool by 5.5M

Entered securities purchase agreement for $1M private placement; initial closing of $125K at $0.60/share.
February 13, 2026, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 3.02 item 9.01 ◈ Equity Issuances ×3◈ Material Agreements

Brainstorm Cell Therapeutics raises $1M in private placement at $0.60 per share

Entered Securities Purchase Agreement for $1M total, closings of $500k each on Feb 9, 2026 and ~30 days later.
January 9, 2026, 6:59 PM ET debt materiality 0.75 negative item 1.01 item 3.02 item 9.01 ◈ Material Agreements ×3◈ Equity Issuances

BCLI issues three convertible notes to institutional investors, total ~$329K principal

Vanquish Funding: $94.3K note (12% OID), convertible at 65% of lowest trading price upon default, matures Oct 2026.
November 14, 2025, 6:59 PM ET debt materiality 0.60 negative item 1.01 item 2.02 item 3.02 item 9.01 ◈ Equity Issuances

Brainstorm Cell Therapeutics issues $143,750 note to Labrys Fund II, reports Q3 2025 results

Entered securities purchase agreement with Labrys Fund II for a promissory note of $143,750, including $18,750 original issue discount, receiving net proceeds of $121,500.
November 6, 2025, 6:59 PM ET debt materiality 0.55 neutral item 1.01 item 3.02 item 9.01

Brainstorm Cell Therapeutics issues $182,400 convertible note to Vanquish Funding

Issued $182,400 promissory note (incl. $22,400 OID) to Vanquish Funding; net proceeds ~$155,000 after $5,000 fees.
August 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

BrainStorm Q2 net loss $2.9M; FDA clears Phase 3b NurOwn trial

Cash and equivalents total $1.03M as of June 30, 2025.
July 17, 2025, 7:59 PM ET other material materiality 0.85 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

BrainStorm delisted from Nasdaq; shares to trade on OTCQB from July 18

Delisting due to non-compliance with Nasdaq minimum shareholder equity rule (Rule 5550(b)(1)).
June 25, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.07 item 9.01

Brainstorm Cell shareholders approve 2M share increase in equity plan pool

Shareholders approved increasing the shared pool under the 2014 plans by 2M shares, to 2,906,666 shares.
June 16, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

BrainStorm reports 90% of ALS patients in NurOwn EAP survived over 5 years

9 of 10 NurOwn EAP participants survived >5 years from symptom onset vs. ~10% typical survival in ALS.
May 19, 2025, 7:59 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

BrainStorm receives FDA clearance to initiate Phase 3b trial of NurOwn for ALS

FDA cleared Phase 3b trial under Special Protocol Assessment (SPA); endpoints agreed for future BLA.
May 15, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

BrainStorm Q1 net loss $2.9M; advances NurOwn Phase 3b trial with IND amendment

Net loss of $2.9M ($0.45/share) improved vs $3.4M ($0.75/share) in Q1 2024.
April 21, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.03 item 5.08 item 9.01 ◈ Governance Changes

Brainstorm Cell Therapeutics amends bylaws to reduce quorum to 1/3; sets 2025 annual meeting for June 25

Board approved reducing stockholder quorum from majority to one-third of outstanding shares.
March 31, 2025, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 3.02 item 9.01

Brainstorm Cell Therapeutics enters warrant inducement deal for ~$1.64M gross proceeds

Holder to exercise existing warrants for 1,381,383 shares; new warrants at 200% of exercised shares.
March 31, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Brainstorm Cell reports FY2024 net loss $11.6M; cash only $0.4M; raises $1.64M via warrant inducement

Net loss of $11.6M ($2.31 per share) improved from $17.2M loss ($6.00 per share) in 2023.
March 27, 2025, 7:59 PM ET regulatory materiality 0.65 neutral item 8.01

Nasdaq panel grants Brainstorm Cell Therapeutics extension to June 30, 2025 to regain listing compliance

Nasdaq Hearings Panel granted extension to June 30, 2025 to regain compliance with $35M minimum Market Value of Listed Securities.
January 21, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices ×2

BCLI fails to regain Nasdaq MVLS compliance; delisting stayed pending Feb 25 hearing

Company previously failed to meet Nasdaq's minimum market value of listed securities requirement by Jan 14, 2025.
January 15, 2025, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices ×2

Brainstorm Cell receives Nasdaq delisting notice for failure to meet MVLS minimum

Nasdaq notified BCLI on Jan 15, 2025 that it failed to regain compliance with the $35M MVLS requirement by the Jan 14 deadline.
November 14, 2024, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

BrainStorm Q3 net loss widens to $2.7M, cash at $0.35M; advancing NurOwn Phase 3b trial

Cash, equivalents, restricted cash only $0.35M as of Sept 30, 2024; net loss $2.7M ($0.51/shr) vs $1.2M ($0.45) YoY.
October 30, 2024, 7:59 PM ET regulatory materiality 0.65 positive item 3.01 item 9.01

BrainStorm regains Nasdaq minimum bid price compliance; listing continues

Received Nasdaq notice of compliance on Oct 29, 2024; common stock continues on Nasdaq Capital Market.
October 1, 2024, 7:59 PM ET other materiality 0.20 neutral item 7.01 item 9.01

Brainstorm Cell publishes corporate presentation; no material new facts disclosed

Company released a corporate presentation on October 1, 2024, furnished as Exhibit 99.1.
October 1, 2024, 7:59 PM ET other material materiality 0.60 neutral item 3.01 item 5.03 item 3.03 item 9.01

Brainstorm Cell Therapeutics effects 1-for-15 reverse stock split to meet Nasdaq bid price requirement

Reverse stock split at 1:15 ratio effective 11:59 p.m. ET on September 30, 2024.
September 26, 2024, 7:59 PM ET other material materiality 0.55 negative item 8.01

Brainstorm Cell Therapeutics announces 1-for-15 reverse stock split effective Sept 30

Board approved 1-for-15 reverse stock split on Sept 23, 2024; stockholders authorized at Sept 16 meeting.
September 16, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.03 item 5.07 item 9.01

Brainstorm Cell shareholders OK 150M authorized share increase, reverse split, equity plan boost

Stockholders approved increasing authorized common shares from 100M to 250M.
August 14, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

BrainStorm Q2 net loss narrows to $2.5M; FDA alignment on NurOwn Phase 3b trial CMC

Net loss for Q2 2024 was $2.5M ($0.04/sh), compared to $5.3M ($0.13/sh) in Q2 2023.
July 30, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.08 item 9.01

Brainstorm Cell Therapeutics sets 2024 annual meeting for Sep 16, 2024

Annual meeting to be held virtually on Sep 16, 2024 at 10:00 a.m. Eastern time.
July 19, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01

Nasdaq warns Brainstorm Cell Therapeutics of MVLS deficiency; 180 days to comply

Received Nasdaq deficiency notice on July 18, 2024 for MVLS below $35M minimum.
June 28, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 8.01 item 9.01

BrainStorm Cell Therapeutics raises $4.0M in registered direct offering and warrants

Gross proceeds ~$4.0M from sale of 11.1M shares or pre-funded warrants at $0.36/share.
June 26, 2024, 7:59 PM ET regulatory materiality 0.60 positive item 8.01 item 9.01

BrainStorm reaches alignment with FDA on CMC for NurOwn Phase 3b ALS trial

FDA alignment on Chemistry, Manufacturing, and Controls (CMC) for Phase 3b trial of NurOwn for ALS.
June 20, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change

Brainstorm Cell Therapeutics appoints Hartoun Hartounian as EVP and COO, effective June 24, 2024

Hartoun Hartounian appointed EVP and COO, effective June 24, 2024.
June 4, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

Nasdaq grants Brainstorm Cell Therapeutics temporary exception until Oct 21 for bid price compliance

Company received delisting notice on May 1 for failing $1 minimum bid price; appealed on May 2.
May 3, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Brainstorm Cell receives Nasdaq delisting notice; files appeal to stay trading

Received Staff Letter on May 1, 2024 for failing to meet $1.00 minimum bid price by April 29, 2024.
April 17, 2024, 7:59 PM ET leadership materiality 0.70 positive item 5.02 item 8.01 item 9.01 ◈ executive_change ×2

BrainStorm CEO Steps Down, CMO Promoted; Phase 3b Trial for NurOwn Planned

Co-CEO Stacy Lindborg resigns effective May 9, 2024, but will join the Board of Directors.
April 11, 2024, 7:59 PM ET other materiality 0.50 positive item 8.01 item 9.01

Brainstorm Cell regains Nasdaq minimum market value compliance

Received Nasdaq notification on April 10, 2024 that it regained compliance with Listing Rule 5550(b)(2).
April 9, 2024, 7:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

BrainStorm announces FDA SPA agreement for Phase 3b trial of NurOwn in ALS

FDA agreed on Phase 3b trial design under Special Protocol Assessment (SPA) for NurOwn in ALS.
April 2, 2024, 7:59 PM ET other material materiality 0.25 neutral item 1.01 item 9.01 ◈ Material Agreements

Brainstorm Cell Therapeutics removes Leerink Partners as ATM selling agent

Amendment No. 1 to Distribution Agreement dated April 2, 2024 removes Leerink Partners as agent.
April 1, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases

Brainstorm Cell reports FY2023 net loss of $17.2M; cash drops to $1.45M; awaits FDA SPA

Net loss $17.2M ($0.40/share) vs $24.3M ($0.66) in 2022; no revenue (pre-revenue biotech).
December 20, 2023, 6:59 PM ET other material materiality 0.75 neutral item 5.07 item 7.01 item 8.01 item 9.01 ◈ Shareholder Votes ×2

BrainStorm plans Phase 3b NurOwn trial, SPA submission in Feb 2024 after ADCOM setback

CEO Chaim Lebovits letter outlines Phase 3b trial as most expedient path to FDA approval for NurOwn ALS therapy.
November 22, 2023, 6:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

BrainStorm announces FDA meeting on Dec 6 to discuss SPA for NurOwn Phase 3b in ALS

FDA granted in-person meeting scheduled for December 6, 2023, to discuss NurOwn's regulatory path in ALS.
November 14, 2023, 6:59 PM ET other material materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Brainstorm reports Q3 net loss $1.2M; withdraws NurOwn BLA for ALS, cuts 30% headcount

Withdrew BLA for NurOwn in ALS after FDA advisory committee vote; FDA invites expedited meeting for path forward.
November 9, 2023, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Brainstorm Cell Nasdaq delisting risk: MVLS below $35M minimum

Received Nasdaq deficiency notice on Nov 6, 2023 for MVLS below $35M required for continued listing.
November 3, 2023, 7:59 PM ET regulatory materiality 0.60 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Brainstorm Cell receives Nasdaq bid price deficiency notice; has until April 29, 2024 to comply

Nasdaq notified BCLI on Nov 1, 2023 of non-compliance with $1.00 minimum bid price rule (Listing Rule 5550(a)(2)).
October 24, 2023, 7:59 PM ET other material materiality 0.75 negative item 2.05 item 5.02 item 7.01 item 9.01 ◈ executive_change◈ Restructurings & Charges

BrainStorm cuts 30% headcount, CMO departs, plans NurOwn Phase 3b trial

Reduction in force of ~30% with estimated severance costs of $450k-$900k, substantially complete by end of 2023.
August 14, 2023, 7:59 PM ET earnings materiality 0.85 neutral item 2.02 item 9.01 ◈ Earnings Releases

BrainStorm Q2 net loss $5.3M; NurOwn ADCOM set for Sep 27, PDUFA Dec 8

Net loss of $5.3M ($0.13 per share) vs $7.0M in Q2 2022.
July 19, 2023, 7:59 PM ET other material materiality 0.45 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements ×2

BrainStorm Cell Therapeutics announces $7.5M registered direct offering of common stock and warrants

4,054,055 shares at $1.85 each, each with a warrant to purchase one share at $2.00 for five years.
June 20, 2023, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01 ◈ executive_change ×2

BrainStorm appoints Nir Naor as Board member and Audit Committee chair; Taub resigns

Malcolm Taub resigned from Board effective June 15, 2023; decision not due to any disagreement with the Company.
June 6, 2023, 7:59 PM ET regulatory materiality 0.75 neutral item 7.01 item 9.01

FDA schedules advisory committee meeting for BrainStorm's NurOwn BLA on Sept 27, 2023

FDA Cellular, Tissue and Gene Therapies Advisory Committee to review NurOwn BLA for ALS on September 27, 2023.
May 24, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change

Brainstorm Cell Therapeutics COO David Setboun resigns effective May 31, 2023

David Setboun, PhD, MBA, EVP and COO, notified resignation on May 18, 2023.